Advertisement

Preoperative Systemic Therapy for Breast Cancer

Published:October 17, 2022DOI:https://doi.org/10.1016/j.suc.2022.08.017

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gralow J.R.
        • Burstein H.J.
        • Wood W.
        • et al.
        Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
        J Clin Oncol. 2008; 26: 814-819
        • Fernandez-Martinez A.
        • Krop I.E.
        • Hillman D.W.
        • et al.
        Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer.
        J Clin Oncol. 2020; 38: 4184-4193
        • Sikov W.M.
        • Berry D.A.
        • Perou C.M.
        • et al.
        Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
        J Clin Oncol. 2015; 33: 13-21
        • Geyer C.E.
        • Sikov W.M.
        • Huober J.
        • et al.
        Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
        Ann Oncol. 2022; 33: 384-394
        • Boughey J.C.
        • Suman V.J.
        • Mittendorf E.A.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
        JAMA. 2013; 310: 1455-1461
        • Kuehn T.
        • Bauerfeind I.
        • Fehm T.
        • et al.
        Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
        Lancet Oncol. 2013; 14: 609-618
        • Boileau J.F.
        • Poirier B.
        • Basik M.
        • et al.
        Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
        J Clin Oncol. 2015; 33: 258-264
        • von Minckwitz G.
        • Untch M.
        • Blohmer J.U.
        • et al.
        Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
        J Clin Oncol. 2012; 30: 1796-1804
        • Cortazar P.
        • Zhang L.
        • Untch M.
        • et al.
        Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
        Lancet. 2014; 384 (Epub 2014 Feb 14. Erratum in: Lancet. 2019 Mar 9;393(10175):986): 164-172https://doi.org/10.1016/S0140-6736(13)62422-8
        • Symmans W.F.
        • Peintinger F.
        • Hatzis C.
        • et al.
        Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
        J Clin Oncol. 2007; 25: 4414-4422
        • Symmans W.F.
        • Wei C.
        • Gould R.
        • et al.
        Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.
        J Clin Oncol. 2017; 35: 1049-1060
        • Gadi V.K.
        • Davidson N.E.
        Practical Approach to Triple-Negative Breast Cancer.
        J Oncol Pract. 2017; 13: 293-300
        • Lehmann B.D.
        • Bauer J.A.
        • Chen X.
        • et al.
        Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
        J Clin Invest. 2011; 121: 2750-2767
        • Burstein M.D.
        • Tsimelzon A.
        • Poage G.M.
        • et al.
        Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
        Clin Cancer Res. 2015; 21: 1688-1698
        • Cheang M.C.
        • Martin M.
        • Nielsen T.O.
        • et al.
        Defining breast cancer intrinsic subtypes by quantitative receptor expression.
        Oncologist. 2015; 20: 474-482
        • Peto R.
        • Davies C.
        • Godwin J.
        • et al.
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
        Lancet. 2012; 379: 432-444
        • Blum J.L.
        • Flynn P.J.
        • Yothers G.
        • et al.
        Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
        J Clin Oncol. 2017; 35: 2647-2655
        • Hurley J.
        • Reis I.M.
        • Rodgers S.E.
        • et al.
        The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
        Breast Cancer Res Treat. 2013; 138: 783-794
        • Shepherd J.H.
        • Ballman K.
        • Polley M.C.
        • et al.
        CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
        J Clin Oncol. 2022; 40: 1323-1334
        • von Minckwitz G.
        • Schneeweiss A.
        • Loibl S.
        • et al.
        Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 747-756
        • Loibl S.
        • Weber K.E.
        • Timms K.M.
        • et al.
        Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
        Ann Oncol. 2018; 29: 2341-2347
        • Farkona S.
        • Diamandis E.P.
        • Blasutig I.M.
        Cancer immunotherapy: the beginning of the end of cancer?.
        BMC Med. 2016; 14: 73
        • Nanda R.
        • Liu M.C.
        • Yau C.
        • et al.
        Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.
        JAMA Oncol. 2020; 6: 676-684
        • Schmid P.
        • Cortes J.
        • Pusztai L.
        • et al.
        KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer.
        N Engl J Med. 2020; 382: 810-821
        • Schmid P.
        • Cortes J.
        • Dent R.
        • et al.
        KEYNOTE-522 investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
        N Engl J Med. 2022; 386: 556-567
        • National Comprehensive Cancer Network (NCCN)
        NCCN Clinical practice guidelines in oncology. Breast cancer version 4.2022.
        (Accessed August 15, 2022)
        • Masuda N.
        • Lee S.J.
        • Ohtani S.
        • et al.
        Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
        N Engl J Med. 2017; 376: 2147-2159
        • Joensuu H.
        • Kellokumpu-Lehtinen P.L.
        • Huovinen R.
        • et al.
        Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
        J Clin Oncol. 2012; 30: 11-18
        • O'Shaughnessy J.
        • Koeppen H.
        • Xiao Y.
        • et al.
        Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
        Clin Cancer Res. 2015; 21: 4305-4311
        • Natori A.
        • Ethier J.L.
        • Amir E.
        • et al.
        Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials.
        Eur J Cancer. 2017; 77: 40-47
        • Tutt A.N.J.
        • Garber J.E.
        • Kaufman B.
        • et al.
        OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
        N Engl J Med. 2021; 384: 2394-2405
        • Slamon D.J.
        • Godolphin W.
        • Jones L.A.
        • et al.
        Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
        Science. 1989; 244: 707-712
        • Korde L.A.
        • Somerfield M.R.
        • Carey L.A.
        • et al.
        Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline.
        J Clin Oncol. 2021; 39: 1485-1505
        • Perez E.A.
        • Romond E.H.
        • Suman V.J.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
        J Clin Oncol. 2014; 32: 3744-3752
        • von Minckwitz G.
        • Procter M.
        • de Azambuja E.
        • et al.
        APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
        N Engl J Med. 2017; 377: 122-131
        • Piccart M.
        • Procter M.
        • Fumagalli D.
        • et al.
        APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
        J Clin Oncol. 2021; 39: 1448-1457
        • Gianni L.
        • Eiermann W.
        • Semiglazov V.
        • et al.
        Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
        Lancet. 2010; 375: 377-384
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 25-32
        • Guarneri V.
        • Griguolo G.
        • Miglietta F.
        • et al.
        Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
        ESMO Open. 2022; 7: 100433
        • Chan A.
        • Delaloge S.
        • Holmes F.A.
        • et al.
        • ExteNET Study Group
        Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2016; 17: 367-377
        • Hurvitz S.A.
        • Martin M.
        • Symmans W.F.
        • et al.
        Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
        Lancet Oncol. 2018; 19: 115-126
      1. Metzger Filho O, Viale G, Trippa L, et al: HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. 2019 ASCO Annual Meeting. Abstract 502. Presented June 3, 2019.

        • Slamon D.
        • Eiermann W.
        • Robert N.
        • et al.
        • Breast Cancer International Research Group
        Adjuvant trastuzumab in HER2-positive breast cancer.
        N Engl J Med. 2011; 365: 1273-1283
        • van Ramshorst M.S.
        • van der Voort A.
        • van Werkhoven E.D.
        • et al.
        Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 1630-1640
        • van der Voort A.
        • van Ramshorst M.S.
        • van Werkhoven E.D.
        • et al.
        Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial.
        JAMA Oncol. 2021; 7: 978-984
        • von Minckwitz G.
        • Huang C.S.
        • Mano M.S.
        • et al.
        KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
        N Engl J Med. 2019; 380: 617-628
        • Spring L.M.
        • Gupta A.
        • Reynolds K.L.
        • et al.
        Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis.
        JAMA Oncol. 2016; 2: 1477-1486
        • Colleoni M.
        • Viale G.
        • Zahrieh D.
        • et al.
        Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
        Clin Cancer Res. 2004; 10: 6622-6628
        • Colleoni M.
        • Viale G.
        • Zahrieh D.
        • et al.
        Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
        Ann Oncol. 2008; 19: 465-472
        • Cataliotti L.
        • Buzdar A.U.
        • Noguchi S.
        • et al.
        Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
        Cancer. 2006; 106: 2095-2103
        • Smith I.E.
        • Dowsett M.
        • Ebbs S.R.
        • et al.
        • IMPACT Trialists Group
        Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
        J Clin Oncol. 2005; 23: 5108-5116
        • Chia Y.H.
        • Ellis M.J.
        • Ma C.X.
        Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
        Br J Cancer. 2010; 103: 759-764
        • Suman V.J.
        • Ellis M.J.
        • Ma C.X.
        The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.
        Chin Clin Oncol. 2015; 4: 34
        • Ellis M.J.
        • Suman V.J.
        • Hoog J.
        • et al.
        Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the american college of surgeons oncology group Z1031 trial (Alliance).
        J Clin Oncol. 2017; 35: 1061-1069
        • Hosford S.R.
        • Miller T.W.
        Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
        Pharmgenomics Pers Med. 2014; 7: 203-215
        • Johnston S.R.D.
        • Harbeck N.
        • Hegg R.
        • Toi M.
        • Martin M.
        • Shao Z.M.
        • Zhang Q.Y.
        • Martinez Rodriguez J.L.
        • Campone M.
        • Hamilton E.
        • Sohn J.
        • Guarneri V.
        • Okada M.
        • Boyle F.
        • Neven P.
        • Cortés J.
        • Huober J.
        • Wardley A.
        • Tolaney S.M.
        • Cicin I.
        • Smith I.C.
        • Frenzel M.
        • Headley D.
        • Wei R.
        • San Antonio B.
        • Hulstijn M.
        • Cox J.
        • O'Shaughnessy J.
        • Rastogi P.
        • Investigators
        • monarchE Committee Members
        Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
        J Clin Oncol. 2020; 38: 3987-3998
        • Hurvitz S.A.
        • Martin M.
        • Press M.F.
        • et al.
        Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
        Clin Cancer Res. 2020; 26: 566-580
        • Johnston S.
        • Puhalla S.
        • Wheatley D.
        • et al.
        Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
        J Clin Oncol. 2019; 37: 178-189
        • Ellis M.J.
        • Tao Y.
        • Luo J.
        • et al.
        Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
        J Natl Cancer Inst. 2008; 100: 1380-1388
        • Khan Q.J.
        • O’Dea A.
        • Bardia A.
        • et al.
        Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
        J Clin Oncol. 2020; 38: 505
        • André F.
        • Ciruelos E.
        • Rubovszky G.
        • et al.
        SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
        N Engl J Med. 2019; 380: 1929-1940
        • Saura C.
        • Hlauschek D.
        • Oliveira M.
        • et al.
        Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
        Lancet Oncol. 2019; 20: 1226-1238
        • Rothé F.
        • Silva M.J.
        • Venet D.
        • et al.
        Circulating Tumor DNA in HER2-Amplified Breast Cancer: a translational research substudy of the NeoALTTO Phase III Trial.
        Clin Cancer Res. 2019; 25: 3581-3588
        • Magbanua M.J.M.
        • Swigart L.B.
        • Wu H.T.
        • et al.
        Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
        Ann Oncol. 2021; 32: 229-239
        • Lipsyc-Sharf M.
        • De Bruin E.
        • Santos K.
        • et al.
        Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
        J Clin Oncol. 2022; 40: abstr 103
      2. Wolf DM, Yau C, Brown-Swigart L, Hirst G, Buxton M, Paoloni M, I-SPY2 TRIAL Investigators, Olopade O, DeMichele A, Symmans F, Rugo H, Berry D, Esserman L, van t Veer L. Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer [Abstract]. In: AACR 107th Annual Meeting 2016 April 16-20, Abstract nr 859.

        • Whitworth P.W.
        • Beitsch P.D.
        • Pellicane J.V.
        • et al.
        • NBRST Investigators Group
        Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
        JCO Precis Oncol. 2022; 6: e2100463
        • Denkert C.
        • von Minckwitz G.
        • Darb-Esfahani S.
        • et al.
        Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
        Lancet Oncol. 2018; 19: 40-50